While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...

RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.

A new paper published in Nature Biotechnology this week titled, “Template-independent enzymatic synthesis of RNA oligonucleotides,” provides details of a method for synthesizing single-stranded RNA ...

President and CEO Alison Moore outlined the company’s strategic focus on RNA medicines manufacturing at TD Cowen’s 46th ...

Inside every cell, thousands of molecular signals collide, overlap, and compensate, obscuring the true drivers of gene expression. Scientists have now developed a way to silence that cellular noise, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...

A single enzyme that can generate all four nucleotide triphosphates, the building blocks of ribonucleic acid (RNA), was identified by researchers at the Institute of Science Tokyo. By using ...

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...

2026年3月3日星期二，Codexis (NASDAQ:CDXS)在TD Cowen第46届年度医疗保健会议上进行了展示。该公司概述了其向RNA药物的战略转型，强调了这一快速扩张市场中的机遇和挑战。首席执行官Alison Moore重点介绍了公司创新的ECO Synthesis平台，该平台旨在提高RNA治疗药物的生产能力，同时也承认制药生物催化领域竞争加剧。

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...